Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Exploring the role of Eli Lilly's Jaypirca (Pirtobrutinib) in Chronic Lymphocytic Leukemia (CLL) Management

Ticker(s): LLY

Who's the expert?

Institution: Case Western Reserve University School of Medicine

Clinical Professor at Case Comprehensive Cancer Center
Treats over 50 patients a year with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)
Research interests are focused on early phase cancer therapeutics, cellular and immunotherapies for blood cancers and other non-malignant disorders; laboratory-based translational researches in normal and cancer stem cell signaling profiles and pre-clinical animal models for therapeutics.

Interview Goal

This call will discuss the current treatment landscape and the potential of Jaypirca (pirtobrutinib), a non-covalent (reversible) BTK inhibitor approved for the treatment of CLL.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.